Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up – Still a Buy?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF)’s share price gapped up before the market opened on Wednesday . The stock had previously closed at $14.71, but opened at $15.67. Ono Pharmaceutical shares last traded at $15.67, with a volume of 416 shares traded.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, Ono Pharmaceutical has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Stock Performance

The firm has a market capitalization of $7.36 billion, a PE ratio of 14.92 and a beta of 0.33. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The company has a 50-day moving average of $14.39 and a 200 day moving average of $14.80.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.